We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-9.1%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$377M
AUM Growth
-$101M
Cap. Flow
-$18.7M
Cap. Flow %
-4.96%
Top 10 Hldgs %
50.73%
Holding
91
New
7
Increased
20
Reduced
15
Closed
11
Avg Time Held
8.2 quarters
Top 10 Avg Time Held
4.9 quarters
Top 20 Avg Time Held
6.6 quarters

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$5.15M
2
ALEC icon
Alector
ALEC
+$3.01M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$3M
4
KALV icon
KalVista Pharmaceuticals
KALV
+$2.61M
5
KRTX icon
Karuna Therapeutics, Inc. Common Stock
KRTX
+$2.49M

Top Sells

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$10.6M
2
TBIO icon
Translate Bio, Inc. Common Stock
TBIO
+$10.4M
3
LMNX
Luminex Corp
LMNX
+$5.12M
4
PRQR icon
ProQR Therapeutics
PRQR
+$4.81M
5
TVRD icon
Tvardi Therapeutics
TVRD
+$4.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.92%
2 Miscellaneous 3.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
STXS icon
1
Stereotaxis
STXS
$104M
$73.6M 19.53%
13,680,554
– –
2013 Q2
33 quarters
BPMC icon
2
DELISTED
Blueprint Medicines
BPMC
$21.3M 5.64%
206,911
-1,000
-0.5% -$93.1K
2016 Q4
19 quarters
FATE icon
3
Fate Therapeutics
FATE
$231M
$20.4M 5.41%
344,360
+30,000
+10% +$2.35M
2019 Q2
9 quarters
BHVN icon
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$12.2M 3.25%
88,100
-6,000
-6% -$749K
2018 Q2
13 quarters
DRNA
5
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$11.8M 3.14%
587,456
+76,700
+15% +$2.12M
2018 Q2
13 quarters
IDYA icon
6
IDEAYA Biosciences
IDYA
$3.27B
$11.7M 3.11%
460,061
+128,400
+39% +$3M
2020 Q3
4 quarters
DXCM icon
7
DexCom
DXCM
$31.7B
$11.6M 3.07%
84,552
– –
2017 Q3
16 quarters
MORF icon
8
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$10.3M 2.73%
181,467
– –
2020 Q4
3 quarters
NRIX icon
9
Nurix Therapeutics
NRIX
$2.56B
$9.18M 2.43%
306,320
– –
2021 Q1
2 quarters
KRTX icon
10
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$9.12M 2.42%
74,585
+21,585
+41% +$2.49M
2020 Q1
6 quarters
NBIX icon
11
Neurocrine Biosciences
NBIX
$13.7B
$8.12M 2.15%
84,655
+11,000
+15% +$1.04M
2016 Q1
22 quarters
SAGE icon
12
DELISTED
Sage Therapeutics
SAGE
$7.99M 2.12%
180,306
+10,000
+6% +$459K
2017 Q4
15 quarters
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
$7.12M 1.89%
119,615
– –
2018 Q1
14 quarters
IBB icon
14
iShares Biotechnology ETF
IBB
$10.4B
$6.61M 1.75%
40,900
– –
2016 Q4
19 quarters
CSII
15
DELISTED
Cardiovascular Systems, Inc.
CSII
$6.36M 1.69%
193,741
+44,041
+29% +$1.64M
2018 Q2
13 quarters
CYTK icon
16
Cytokinetics
CYTK
$8.79B
$6.25M 1.66%
+175,000
New +$5.15M
2021 Q3
0 quarters
XENE icon
17
Xenon Pharmaceuticals
XENE
$3.26B
$6.21M 1.65%
406,535
– –
2015 Q3
24 quarters
AFMD icon
18
DELISTED
Affimed
AFMD
$5.96M 1.58%
96,486
– –
2019 Q4
7 quarters
RVMD icon
19
Revolution Medicines
RVMD
$41.7B
$5.77M 1.53%
209,731
– –
2020 Q4
3 quarters
FSTX
20
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$5.08M 1.35%
693,785
-20,500
-3% -$141K
2021 Q2
1 quarter
ATRC icon
21
AtriCure
ATRC
$2.92B
$5.01M 1.33%
72,029
-19,500
-21% -$1.5M
2013 Q2
33 quarters
OTIC
22
DELISTED
Otonomy, Inc.
OTIC
$4.57M 1.21%
2,379,392
– –
2019 Q4
7 quarters
RCUS icon
23
Arcus Biosciences
RCUS
$2.86B
$4.31M 1.14%
123,700
+4,000
+3% +$124K
2020 Q1
6 quarters
LKFT icon
24
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$4.09M 1.08%
77,675
– –
2015 Q3
24 quarters
ARAY icon
25
Accuray
ARAY
$21.5M
$3.72M 0.99%
941,800
– –
2019 Q2
9 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, DAFNA Capital Management held 91 positions worth $377M, down 21% from $478M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management withdrew a net $18.7M in Q3 2021, closing 11 positions and reducing 15 holdings. Its most notable exit was Theravance Biopharma, an estimated $10.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in Cytokinetics worth $6.25M.

  • DAFNA Capital Management's largest Q3 2021 buy was Cytokinetics: 175,000 shares worth $6.25M.
  • DAFNA Capital Management added most to IDEAYA Biosciences in Q3 2021, an estimated $3M increase.
  • DAFNA Capital Management's biggest Q3 2021 reduction was ProQR Therapeutics, cutting an estimated $4.81M.
  • DAFNA Capital Management fully exited Theravance Biopharma in Q3 2021, selling an estimated $10.6M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $377M portfolio in Q3 2021.
  • DAFNA Capital Management opened 7 new positions and closed 11 in Q3 2021.
  • DAFNA Capital Management's portfolio value fell 21% quarter-over-quarter to $377M.

Based on DAFNA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.